Cardio-oncology & otherSecondary analysis
Anthracycline Dose, Myocardial Injury, and Change in Left Ventricular Function in the Cardiac CARE Trial
- Secondary analysis of the Cardiac CARE randomised trial
- prospective
- multicentre
- open-label
- blinded-endpoint
Authors' conclusion
Hs-cTnI levels were not associated with cumulative anthracycline dose and were only weakly associated with LVEF decline at 6 months.
Study context
- Population
- Patients with elevated baseline high-sensitivity cardiac troponin I (hs-cTnI) undergoing high-dose anthracycline chemotherapy171 received ≥3 cycles
- Participants
- 175 patients
- Primary endpoint
- Associations between hs-cTnI, cumulative anthracycline dose, number of treatment cycles and change in left ventricular (LV) function (CMR)
- Follow-up
- 6 months post-chemotherapy
Primary result
As reported in the abstract
Median cumulative epirubicin-equivalent dose
600 mg/m² (Q1-Q3: 513-660 mg/m²)
Peak hs-cTnI 2 months after chemotherapy, median
14.0 ng/L [Q1-Q3: 9.0-30.5 ng/L]
LV ejection fraction (LVEF) <50%
0
LVEF decline >10%
24 of 171 patients (14.0%)
Original publication
Anthracycline Dose, Myocardial Injury, and Change in Left Ventricular Function in the Cardiac CARE Trial. JACC CardioOncol. Published 14 August 2025. doi:10.1016/j.jaccao.2025.06.003
Summarised from the published abstract; every number is checked against it